Zhang Youhua, Mazgalev Todor N
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Pacing Clin Electrophysiol. 2004 Mar;27(3):382-93. doi: 10.1111/j.1540-8159.2004.00447.x.
Atrial fibrillation (AF) is the most common arrhythmia. Currently there are two broad strategic treatment options for AF: rhythm control and rate control. For rhythm control, the treatment is directed toward restoring and maintaining the sinus rhythm. For rate control, the intention is to slow ventricular rate while allowing AF to continue. In both cases anticoagulation therapy is recommended. The results of currently available clinical trials demonstrated clearly that rate control is not inferior to rhythm control. Thus, rate control is an acceptable primary therapy for many AF patients. The rate control can be achieved essentially by depressing or modifying the filtering properties of the atrioventricular (AV) node. This can be attained by medications that depress the impulse transmission within the AV node, by anatomic modification of the AV communications, as well as by autonomic manipulations that produce AV node negative dromotropic effect. We are reviewing current clinical and newer experimental modalities aimed at enhancing the lifesaving function of this remarkable nodal structure.
心房颤动(AF)是最常见的心律失常。目前,AF有两种广泛的战略治疗选择:节律控制和心率控制。对于节律控制,治疗旨在恢复并维持窦性心律。对于心率控制,目的是减慢心室率,同时允许AF持续存在。在这两种情况下,均推荐抗凝治疗。目前可用的临床试验结果清楚地表明,心率控制并不劣于节律控制。因此,心率控制是许多AF患者可接受的主要治疗方法。心率控制基本上可以通过抑制或改变房室(AV)结的滤波特性来实现。这可以通过抑制AV结内冲动传导的药物、对AV传导通路进行解剖学改造以及产生AV结负性变传导作用的自主神经操作来实现。我们正在回顾当前旨在增强这个非凡结状结构救生功能的临床和更新的实验方法。